Sep 3, 2009 | Medical News
Uroplasty highlights the result of OrBIT trial of its Urgent PC System
Uroplasty, Inc. , a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today highlighted results published in the September, 2009 edition of THE JOURNAL OF UROLOGY from the OrBIT trial of its Urgent PC System.
Drug News: Fesoterodine for the treatment of overactive bladder
This Article is provided free of charge. Add to File Drawer DRUG NEWS: Fesoterodine for the treatment of overactive bladder On October 31, 2008, the FDA approved fesoterodine fumarate for the treatment of overactive bladder syndrome, which affects about 16% of the adult population, especially the elderly.
Urgent(R) PC and Macroplastique(R) Featured in Numerous IUGA 2009 Sessions
MINNEAPOLIS, July 7 MN-Uroplasty-Inc-IUGA MINNEAPOLIS , /PRNewswire-FirstCall/ -- Uroplasty, Inc.
Pfizer Introduces New Treatment And Support Plan For Patients With Overactive Bladder
Jun 2, 2009 - Pfizer Inc announced today that Toviaz extended release tablets and the YourWay plan , a comprehensive, customizable support plan for overactive bladder patients, are available in the United States.
Bladder Urothelial Cells From Patients With Interstitial Cystitis...
UroToday.com - The presence of muscarinic receptors on bladder urothelial cells suggests BUC may be a target for antimuscarinics.
Also on Topix